Read + Share
Amedeo Smart
Independent Medical Education
Kim SJ, Lim JQ, Yoon SE, Yang DH, et al. Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma. Blood 2025 Mar 12:blood.2024027109. doi: 10.1182/blood.2024027109.PMID: 40073374
Email
LinkedIn
Privacy Policy